Articles related to VIRUSES

Symptom onset typically occurs within 12-48 hours of exposure, with most patients experiencing complete recovery within 72 hours when properly managed.

The recent uncovering of KSHV’s method of commandeering cell metabolism for cancer progression not only highlights a novel therapeutic target but also emphasizes the need for vigilant monitoring in immunocompromised patients, where such viral activations are more likely to precipitate aggressive cancers.

In the battle against recurrent herpes simplex virus infections, chronic suppressive therapy emerges as a pivotal strategy, diminishing both the physical burden of outbreaks and the psychological weight of potential transmission.

New research suggests that the COVID-19 virus and its remnant spike protein may bind to and kill lymphocytes, leading to lymphopenia.

The potential of the antiviral combo in reducing the risk of thromboembolic events among post-COVID-19 patients is real. Could it pave the way for more targeted therapeutic strategies in managing post-COVID-19 conditions?

Stay informed about the latest advancements in immunization practices. Learn more about the new FDA-approved RSV vaccines and their potential impact on patient care.